Clopidogrel napadisilate monohydrate loaded surface-modified solid dispersion: Physicochemical characterization and in vivo evaluation

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 7, 2015, Pages 1033-1040

  Kim, Young Hun ^a   Kim, Dong Wuk ^a   Kwon, Min Seok ^a   Cho, Kwan Hyung ^b,c   Kim, Jong Oh ^b   Yong, Chul Soon ^b   Choi, Han Gon ^a  

^a Hanyang University   (South Korea)

^b Yeungnam University   (South Korea)

^c Inje University   (South Korea)

Author keywords

Bioavailability; Clopidogrel napadisilate monohydrate; Stability; Surface modified solid dispersion; Water

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CLOPIDOGREL NAPADISILATE MONOHYDRATE; HYDROXYPROPYLMETHYLCELLULOSE; UNCLASSIFIED DRUG; POLYSORBATE; TICLOPIDINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; POWDER DIFFRACTION; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DELIVERY SYSTEMS; HYPROMELLOSE DERIVATIVES; MALE; MICROSCOPY, ELECTRON, SCANNING; PLATELET AGGREGATION INHIBITORS; POLYSORBATES; POWDER DIFFRACTION; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TICLOPIDINE; X-RAY DIFFRACTION;

EID: 84936874660     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b15-00113     Document Type: Article

References (24)

1. Field TS, Nakajima M, Benavente OR. Combination aspirin and clopidogrel for secondary prevention of ischemic stroke. Curr. Treat. Options Cardiovasc. Med., 15, 348-359 (2013).
2. Zuurbier SM, Vermeer SE, Hilkens PH, Algra A, Roos YB. Secondary prevention with clopidogrel after TIA or stroke. Ned. Tijdschr. Geneeskd., 157, A5836 (2013).
3. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J. Pharmaceut. Biomed., 34, 341-348 (2004).
4. Kim YI, Kim KS, Suh KH, Shanmugam S, Woo JS, Yong CS, Choi HG. New clopidogrel napadisilate salt and its solid dispersion with improved stability and bioequivalence to the commercial clopidogrel bisulphate salt in beagle dogs. Int. J. Pharm., 415, 129-139 (2011).
5. Vo CL, Park C, Lee BJ. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm., 85 (3 Pt B), 799-813 (2013).
6. Newa M, Bhandari KH, Kim JO, Im JS, Kim JA, Yoo BK, Woo JS, Choi HG, Yong CS. Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems. Chem. Pharm. Bull., 56, 569-574 (2008).
7. Oh DH, Park YJ, Kang JH, Yong CS, Choi H-G. Physicochemical characterization and in vivo evaluation of flurbiprofen-loaded solid dispersion without crystalline change. Drug Deliv., 18, 46-53 (2011).
8. Yan YD, Sung JH, Kim KK, Kim DW, Kim JO, Lee BJ, Yong CS, Choi H-G. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int. J. Pharm., 422, 202-210 (2012).
9. Kim DW, Kwon MS, Yousaf AM, Balakrishnan P, Park JH, Kim DS, Lee B-J, Park YJ, Yong CS, Kim JO, Choi H-G. Comparison of a solid SMEDDS and solid dispersion for enhanced stability and bioavailability of clopidogrel napadisilate. Carbohydr. Polym., 114, 365-374 (2014).
10. Kiss L, Walter FR, Bocsik A, Veszelka S, Ozsvári B, Puskás LG, Szabó-Révész P, Deli MA. Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells. J. Pharm. Sci., 102, 1173-1181 (2013).
11. Wang H, Wang HS, Liu ZP. Agents that induce pseudo-allergic reaction. Drug Discov. Ther., 5, 211-219 (2011).
12. Sanchez H, Bigard X, Veksler V, Mettauer B, Lampert E, Lonsdorfer J, Ventura-Clapier R. Immunosuppressive treatment affects cardiac and skeletal muscle mitochondria by the toxic effect of vehicle. J. Mol. Cell. Cardiol., 32, 323-331 (2000).
13. Li DX, Jang KY, Kang W, Bae K, Lee MH, Oh YK, Jee JP, Park YJ, Oh DH, Seo YG, Kim YR, Kim JO, Yoo JS, Yong CS, Choi H-G. Enhanced solubility and bioavailability of sibutramine base by solid dispersion system with aqueous medium. Biol. Pharm. Bull., 33, 279-284 (2010).
14. Di Girolamo G, Czerniuk P, Bertuola R, Keller GA. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. Clin. Ther., 32, 161-170 (2010).
15. Joe JH, Lee WM, Park YJ, Joe KH, Oh DH, Seo YG, Woo JS, Yong CS, Choi H-G. Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int. J. Pharm., 395, 161-166 (2010).
16. Li DX, Oh Y-K, Lim S-J, Kim JO, Yang HJ, Sung JH, Yong CS, Choi H-G. Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique. Int. J. Pharm., 355, 277-284 (2008).
17. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50, 47-60 (2000).
18. Park Y-J, Ryu D-S, Li DX, Quan QZ, Oh DH, Kim JO, Seo YG, Lee Y-I, Yong CS, Woo JS, Choi H-G. Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch. Pharm. Res., 32, 893-898 (2009).
19. Kachrimanis K, Nikolakakis I, Malamataris S. Spherical crystal agglomeration of ibuprofen by the solvent-change technique in presence of methacrylic polymers. J. Pharm. Sci., 89, 250-259 (2000).
20. Khan GM, Jiabi Z. Preparation, characterization, and dissolution studies of ibuprofen solid dispersions using polyethylene glycol (PEG), talc, and PEG-talc as dispersion carriers. Drug Dev. Ind. Pharm., 24, 455-462 (1998).
21. Agrawal H, Kaul N, Paradkar A, Mahadik K. Stability indicating HPTLC determination of clopidogrel bisulphate as bulk drug and in pharmaceutical dosage form. Talanta, 61, 581-589 (2003).
22. Singh SS, Sharma K, Barot D, Mohan PR, Lohray VB. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 821, 173-180 (2005).
23. Silvestro L, Gheorghe MC, Tarcomnicu I, Savu S, Savu SR, Iordachescu A, Dulea C. Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Use of incurred samples to test back-conversion. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 878, 3134-3142 (2010).
24. Lim HT, Balakrishnan P, Oh DH, Joe KH, Kim YR, Hwang DH, Lee YB, Yong CS, Choi H-G. Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs. Int. J. Pharm., 397, 225-230 (2010).